Roger Lo on the Evolution of Melanoma During Therapy
Roger Lo, MD, PhD, UCLA Jonsson Comprehensive Cancer Center, discusses the evolution of metastatic melanoma during therapy.
Roger Lo, MD, PhD, UCLA Jonsson Comprehensive Cancer Center, discusses the evolution of metastatic melanoma during therapy.
Because of mutations in the BRAF gene, patients become resistant to anti-BRAF treatment after a period of time and the tumors start to grow again.
Lo and investigators used genomic and epigenomic profiling to detect changes in the genes’ activities inside the tumor and evaluate the function of the immune cells.
They found that the altered tumor cell behavior originates from the gene activity regulatory mechanism called CpG methylation.
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
